Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The University of Cambridge has joined biotechnology company, Elan, to form The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), at the University of Cambridge, England.
Subscribe to our email newsletter
The ten-year collaboration agreement will focus on translational research for innovative therapies for Alzheimer’s and Parkinson’s diseases.
The Cambridge-Elan Centre will discover novel compounds capable of altering the behavior of proteins associated with neurodegenerative disorders that can be developed into new treatments.
The Centre will use Elan’s experience in Alzheimer’s research and University of Cambridge’s expertise in biophysical approaches to study the molecular basis of protein misfolding and aggregation, besides learning its association with the disease.
Elan executive vice president and chief scientific officer Dale Schenk said the deal is in line with their portfolio of programs in neuroscience and supports the process of discovery which would result in a new line of therapeutics.